Volume 31, No 10, Oct 2021

ISSN: 1001-0602 
EISSN: 1748-7838 2018 
impact factor 17.848* 
(Clarivate Analytics, 2019)

Volume 31 Issue 10, October 2021: 1039-1040

RESEARCH HIGHLIGHTS

Neutralizing shapeshifting pericytes enhances glioblastoma therapeutic efficacy

Samuel A. Sprowls^1,2 , Justin D. Lathia^2,3,4,*

¹Department of Basic Pharmaceutical Sciences, School of Pharmacy, Health Sciences Center, West Virginia University, Morgantown, WV, USA
²Department of Cardiovascular & Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, Cleveland, OH, USA
³Rose Ella Burkhardt Brain Tumor & Neuro-Oncology Center, Cleveland Clinic, Cleveland, OH, USA
⁴Case Comprehensive Cancer Center, Cleveland, OH, USA
Correspondence: Justin D. Lathia(lathiaj@ccf.org)

Maraviroc, an FDA-approved therapy, provides a potentially viable treatment option for those diagnosed with glioblastoma harboring a high amount of pericyte support cells.

https://doi.org/10.1038/s41422-021-00538-1

FULL TEXT | PDF

Browse 809